Business Wire: Qlaris Bio Announces Development of Fixed-Dose Combination Therapy with QLS‑111 and Latanoprost for the Treatment of Glaucoma
Qlaris Bio Announces Development of Fixed-Dose Combination Therapy with QLS‑111 and Latanoprost for the Treatment of Glaucoma
News Medical: Fixed-dose combination therapy for high blood pressure linked to lower health services costs
Fixed-dose combination therapy for high blood pressure linked to lower health services costs
Yahoo Finance: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor ...
-Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head ...
Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor ...
asthma, lungs The combination therapy significantly reduced the risk of severe exacerbations and improved lung function. Topline results were announced from two phase 3 studies evaluating a fixed-dose ...
RAPS: In Shift, FDA to Allow Fixed-Dose Combination Drugs to Obtain Five Years of Market Exclusivity
In Shift, FDA to Allow Fixed-Dose Combination Drugs to Obtain Five Years of Market Exclusivity
RAPS: New Fixed-Dose Combination Drugs Now Eligible for 5 Years of Exclusivity, FDA Says
The US Food and Drug Administration (FDA) has finalized a new policy which will for the first time allow new fixed-dose combination (FDC) drugs consisting of at least one new drug product to be ...
New Fixed-Dose Combination Drugs Now Eligible for 5 Years of Exclusivity, FDA Says
Use of fixed-dose combination therapy, including a polypill, significantly cuts the risk of a first major cardiovascular event in people without preexisting disease, according a new meta-analysis. For ...